HPS manufacturing facility expanded
Avecia has expanded its High Potency Substances (HPS) capabilities with completion at Grangemouth, Scotland of a €1.8m early phase manufacturing suite.
The new, multi-product kilo scale suite will supply cytotoxic APIs for Phase I and II clinical trials programmes, together with chemical process development services for pre-clinical r&d materials. The 450m2 cGMP compliant facility has classification throughout to Class 100,000, a high integrity isolation unit, freeze-drying capability, and a Class 10,000 downflow area for low bio-burden processing. Associated HPS developments at Grangemouth include a small-scale cytotoxic fermentation facility; expanded production capacity for late phase/launched cytotoxic drugs and a high containment suite for non-GMP development services. "This is a flexible, multiproduct facility able to service the broadest range of manufacturing technologies, and with particular capability for the new generation of conjugates," said Avecia Pharmaceuticals' high potency actives business manager Charlie Johnson.